vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and ROCKWELL MEDICAL, INC. (RMTI). Click either name above to swap in a different company.
ROCKWELL MEDICAL, INC. is the larger business by last-quarter revenue ($17.3M vs $16.1M, roughly 1.1× Journey Medical Corp). Journey Medical Corp runs the higher net margin — -7.8% vs -9.2%, a 1.5% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs -8.5%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs -18.2%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
DERM vs RMTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $17.3M |
| Net Profit | $-1.2M | $-1.6M |
| Gross Margin | — | 16.8% |
| Operating Margin | -2.8% | — |
| Net Margin | -7.8% | -9.2% |
| Revenue YoY | 27.3% | -8.5% |
| Net Profit YoY | -182.0% | — |
| EPS (diluted) | $-0.04 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $17.3M | ||
| Q4 25 | $16.1M | $18.3M | ||
| Q3 25 | $17.0M | $15.9M | ||
| Q2 25 | $15.0M | $16.1M | ||
| Q1 25 | $13.1M | $18.9M | ||
| Q4 24 | $12.6M | $24.7M | ||
| Q3 24 | $14.6M | $28.3M | ||
| Q2 24 | $14.9M | $25.8M |
| Q1 26 | — | $-1.6M | ||
| Q4 25 | $-1.2M | $-554.0K | ||
| Q3 25 | $-2.3M | $-1.8M | ||
| Q2 25 | $-3.8M | $-1.5M | ||
| Q1 25 | $-4.1M | $-1.5M | ||
| Q4 24 | $1.5M | $-756.0K | ||
| Q3 24 | $-2.4M | $1.7M | ||
| Q2 24 | $-3.4M | $343.0K |
| Q1 26 | — | 16.8% | ||
| Q4 25 | — | 21.1% | ||
| Q3 25 | — | 14.3% | ||
| Q2 25 | — | 15.6% | ||
| Q1 25 | — | 16.1% | ||
| Q4 24 | 82.3% | 14.7% | ||
| Q3 24 | 63.9% | 22.0% | ||
| Q2 24 | 56.0% | 17.6% |
| Q1 26 | — | — | ||
| Q4 25 | -2.8% | -2.2% | ||
| Q3 25 | -9.0% | -9.9% | ||
| Q2 25 | -19.2% | -8.4% | ||
| Q1 25 | -25.3% | -7.2% | ||
| Q4 24 | 17.7% | -2.1% | ||
| Q3 24 | -19.8% | 6.8% | ||
| Q2 24 | -19.7% | 2.0% |
| Q1 26 | — | -9.2% | ||
| Q4 25 | -7.8% | -3.0% | ||
| Q3 25 | -13.6% | -11.0% | ||
| Q2 25 | -25.3% | -9.3% | ||
| Q1 25 | -31.0% | -8.0% | ||
| Q4 24 | 12.1% | -3.1% | ||
| Q3 24 | -16.3% | 5.9% | ||
| Q2 24 | -22.6% | 1.3% |
| Q1 26 | — | $-0.04 | ||
| Q4 25 | $-0.04 | $-0.01 | ||
| Q3 25 | $-0.09 | $-0.05 | ||
| Q2 25 | $-0.16 | $-0.05 | ||
| Q1 25 | $-0.18 | $-0.04 | ||
| Q4 24 | $0.10 | $-0.02 | ||
| Q3 24 | $-0.12 | $0.04 | ||
| Q2 24 | $-0.17 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | — |
| Total DebtLower is stronger | $25.3M | — |
| Stockholders' EquityBook value | $31.9M | $35.9M |
| Total Assets | $94.6M | $57.4M |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $24.1M | $10.7M | ||
| Q3 25 | $24.9M | $13.6M | ||
| Q2 25 | $20.3M | $12.5M | ||
| Q1 25 | $21.1M | $11.4M | ||
| Q4 24 | $20.3M | $15.7M | ||
| Q3 24 | $22.5M | $12.3M | ||
| Q2 24 | $23.9M | $11.9M |
| Q1 26 | — | — | ||
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — |
| Q1 26 | — | $35.9M | ||
| Q4 25 | $31.9M | $37.0M | ||
| Q3 25 | $25.9M | $37.0M | ||
| Q2 25 | $19.2M | $30.4M | ||
| Q1 25 | $21.5M | $31.5M | ||
| Q4 24 | $20.1M | $32.6M | ||
| Q3 24 | $10.9M | $29.1M | ||
| Q2 24 | $11.3M | $23.5M |
| Q1 26 | — | $57.4M | ||
| Q4 25 | $94.6M | $57.1M | ||
| Q3 25 | $85.2M | $57.5M | ||
| Q2 25 | $81.2M | $52.6M | ||
| Q1 25 | $85.0M | $54.0M | ||
| Q4 24 | $80.2M | $59.2M | ||
| Q3 24 | $64.0M | $57.1M | ||
| Q2 24 | $65.2M | $53.0M |
| Q1 26 | — | — | ||
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-6.3M | $2.3M | ||
| Q3 25 | $-2.4M | $-1.3M | ||
| Q2 25 | $-942.0K | $1.8M | ||
| Q1 25 | $-2.8M | $-3.5M | ||
| Q4 24 | $2.2M | $865.0K | ||
| Q3 24 | $-1.2M | $4.3M | ||
| Q2 24 | $-5.2M | $1.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.2M | ||
| Q3 25 | — | $-1.5M | ||
| Q2 25 | — | $1.7M | ||
| Q1 25 | — | $-3.5M | ||
| Q4 24 | — | $470.0K | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | — | $1.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | 12.0% | ||
| Q3 25 | — | -9.6% | ||
| Q2 25 | — | 10.5% | ||
| Q1 25 | — | -18.8% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 14.4% | ||
| Q2 24 | — | 4.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 1.4% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 1.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | 2.57× | ||
| Q2 24 | — | 4.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
RMTI
Segment breakdown not available.
